Capital World Investors Has $28.98 Million Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Capital World Investors lifted its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 69.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,158,699 shares of the company’s stock after buying an additional 473,894 shares during the quarter. Capital World Investors’ holdings in Centessa Pharmaceuticals were worth $28,979,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of CNTA. Millennium Management LLC grew its position in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after buying an additional 210,737 shares during the period. Jane Street Group LLC acquired a new position in Centessa Pharmaceuticals during the first quarter valued at approximately $2,176,000. Geode Capital Management LLC grew its holdings in Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after purchasing an additional 26,994 shares during the period. JPMorgan Chase & Co. grew its holdings in Centessa Pharmaceuticals by 155.4% during the second quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after purchasing an additional 260,702 shares during the period. Finally, Legal & General Group Plc grew its holdings in Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after purchasing an additional 22,205 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insiders Place Their Bets

In related news, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 309,112 shares of company stock valued at $8,424,535. Company insiders own 4.09% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of a number of analyst reports. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price objective for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $35.00 to $42.00 in a report on Monday, April 20th. Guggenheim cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a report on Monday, April 13th. Finally, Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:CNTA opened at $39.76 on Wednesday. The firm has a market cap of $5.93 billion, a price-to-earnings ratio of -22.21 and a beta of 1.11. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $11.77 and a 12 month high of $40.26. The company’s fifty day simple moving average is $39.40 and its 200 day simple moving average is $30.64.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.